Pacira to raise $63m more as Exparel reaches the market and seeks new indication
This article was originally published in Scrip
Executive Summary
The US specialty pharmaceutical company Pacira Pharmaceuticals has launched the analgesic formulation Exparel (bupivacaine liposome injectable suspension), and priced a common stock offering at $9.75 per share to raise up to $62.9 million in net proceeds, all in the space of a week.